267 results on '"Fallone Carlo A"'
Search Results
52. The 2012 Sage Wait Times Program: Survey of Access to Gastroenterology in Canada
53. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
54. Tu1074 Videocapsule Versus Enteroscopy in Patients With Obscure GI Bleeding: Results of a Randomized Controlled Trial
55. Helicobacter pyloriin First Nations and Recent Immigrant Populations in Canada
56. Sequential versus standard triple therapy for Helicobacter pylori eradication
57. Barrett's Esophagus
58. Optimum duration of regimens for Helicobacter pylori eradication
59. A One-Year Economic Evaluation of Six Alternative Strategies for the Management of Uninvestigated Upper Gastrointestinal Symptoms in Canadian Primary Care
60. Survey of Access to GastroEnterology in Canada: The SAGE Wait Times Program
61. Therapies for the eradication of Helicobacter pylori
62. The Potential Impact of Contemporary Developments in the Management of Patients with Gastroesophageal Reflux Disease Undergoing an Initial Gastroscopy
63. Is IBD caused by a Helicobacter pylori infection?
64. Videocapsule Versus Push Enteroscopy in Patients with Obscure GI Bleeding: Planned Interim Analysis of An Outcomes RCT
65. Does Blood Urea Nitrogen Level Predict Severity and High-Risk Endoscopic Lesions in Patients with Nonvariceal Upper Gastrointestinal Bleeding?
66. Wavelet Decomposition for the Analysis of Esophageal Manometric Data in the Study of Gastroesophageal Reflux Disease
67. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting.
68. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease
69. Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults – Update 2004
70. A Sampling of Canadian Practice in Managing Nonvariceal Upper Gastrointestinal Bleeding before Recent Guideline Publication: Is there Room for Improvement?
71. Barrett's Esophagus
72. A Randomized Multicenter Trial to Evaluate Simple Utility Elicitation Techniques in Patients With Gastroesophageal Reflux Disease
73. LEVEL OF ADHERENCE TO GUIDELINES FOR NONVARICEAL UPPER GASTROINTESTINAL BLEEDING PRIOR TO THEIR PUBLICATION
74. Helicobacter pyloriEradication in Non-Ulcer Dyspepsia: Clearing up the Controversy
75. THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES TO MANAGE PATIENTS WITH UNINVESTIGATED DYSPEPSIA: COMPARING THE CANDYS APPROACH TO ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY
76. COST-EFFECTIVENESS OF ALTERNATIVE APPROACHES IN THE MANAGEMENT OF DYSPEPSIA
77. Detection of Helicobacter pylori in the Setting of Acute Upper Gastrointestinal Bleeding
78. The cost-effectiveness of high dose oral proton pump inhibition in high-risk patients with bleeding peptic ulcers having undergone therapeutic endoscopy
79. A Randomized Trial Comparing Seven-Day Ranitidine Bismuth Citrate and Clarithromycin Dual Therapy to Seven-Day Omeprazole, Clarithromycin and Amoxicillin Triple Therapy for the Eradication ofHelicobacter pylori
80. H. pylori-infected gastroesophageal reflux disease patients harbor less virulent strains
81. The CAG Liaison Committee Report: Committed to Cooperation
82. Two Decades ofHelicobacter pylori: A Review of the Fourth Western PacificHelicobacterCongress
83. Gastroesophageal Reflux and Hyperacidity in Chronic Renal Failure
84. A comparison of ranitidine bismuth citrate-clarithromycin (RBC-C) dual therapy vs. omeprazole, clarithromycin, amoxycillin (OCA) triple therapy given for 7 days in the treatment of H. pylori infection
85. Bismuth-Based Quadruple Therapy with Bismuth Subcitrate, Metronidazole, Tetracycline and Omeprazole in the Eradication ofHelicobacter pylori
86. Therapies for the eradication of Helicobacter pylori
87. Genetic Variability Determinants ofHelicobacter pylori:Influence of Clinical Background and Geographic Origin of Isolates
88. Meeting Review –Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000
89. Epidemiology of the Antibiotic Resistance ofHelicobacter pyloriin Canada
90. Host Determinants ofHelicobacter pyloriInfection and Its Clinical Outcome
91. Determinants of Ethnic or Geographical Differences in Infectivity and Transmissibility ofHelicobacter pylori
92. A review of the possible bacterial determinants of clinical outcome inHelicobacter pyloriinfection
93. Gastric Cytoprotection Is Secondary to Increased Mucosal Fluid Secretion: A Study of Six Cytoprotective Agents in the Rat
94. Utility of Serology in DeterminingHelicobacter pyloriEradication after Therapy
95. Hematoxylin and Eosin Staining of Gastric Tissue for the Detection ofHelicobacter pylori
96. Evaluation of IgA and IgG Serology for the Detection ofHelicobacter pyloriInfection
97. The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole.
98. SedationversusNo Sedation in the Performance of Diagnostic Upper Gastrointestinal Endoscopy: A Canadian Randomized Controlled Cost-Outcome Study.
99. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer ...
100. Host Determinants of Helicobacter pylori Infection and Its Clinical Outcome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.